Overview
Synchron's Australian operations and clinical trial hub developed the Stentrode, a minimally invasive endovascular BCI implanted via a blood vessel without open brain surgery. Their device has enabled ALS patients to control computers and smartphones through motor imagery.
More in Brain-Computer Interfaces
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
🧠 Brain-Computer Interfaces
Location
Melbourne, Australia
Funding
Series B · $75M
Website
synchron.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →